North American cancer monoclonal antibodies market is estimated to grow at a CAGR of 9.6% during the forecast period. The increasing prevalence of cancer and increasing research on monoclonal antibodies are some pivotal factors driving market growth. As per the Centers for Disease Control and Prevention (CDC), the number of new cancer incidences in the US is expected to grow from nearly 1.5 million annually in 2010 to 1.9 million annually in 2020. This results in an increasing demand for monoclonal antibody drugs that act as a targeted therapy to destroy cancer cells. Monoclonal antibodies served as one of the established therapeutic strategies for both solid tumors and hematologic malignancies. It is a type of immunotherapy that stimulates the immune system of cancer patients and works to discover and attack cancerous cells. 

Visit for Global Cancer Monoclonal Antibodies Market Report at: https://www.omrglobal.com/industry-reports/cancer-monoclonal-antibodies-market

North American cancer monoclonal antibodies market is segmented based on type and application. Based on type, the market is classified into naked, conjugated, and others. Based on the application, the market is classified into breast cancer, liver cancer, blood cancer, brain cancer, colorectal cancer, and others. Monoclonal antibodies are expected to find significant application in breast cancer. Kadcyla, (also referred to as TDM-1) targets the HER2 protein like Herceptin. These therapies act against the HER2 protein as this protein is found in massive amounts on certain kinds of breast cancer cells. The therapy is utilized for the treatment of HER2-positive breast cancer. Most often monoclonal antibodies are combined with additional cancer-fighting drugs, including chemotherapy. In the US, breast cancer accounted for the largest share of 11.0% or 234,087 in new cancer incidences in 2018, which is contributing to the adoption of monoclonal antibodies therapy in the region.

Some prominent players in the market include Amgen Inc., Eli Lilly & Co., Pfizer Inc., Merck & Co., Inc., and F. Hoffman La-Roche AG. Product launches and partnerships and collaborations are regarded as some potential strategies implemented by the market players to increase their position in the marketplace. For instance, in December 2019, Mylan N.V. and Biocon Ltd. declared the introduction of Ogivri (trastuzumab-dkst) in the US, which is biosimilar to Herceptin (trastuzumab). It was the first biosimilar trastuzumab approved by the US FDA for all indications which includes treatment of HER2-overexpressing metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) and breast cancer. 

Research Methodology

The market study of the North American cancer monoclonal antibodies market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. North American cancer monoclonal Antibodies Market Research and Analysis by Type
2. North American cancer monoclonal Antibodies Market Research and Analysis by Application

The Report Covers

• Comprehensive research methodology of the North American cancer monoclonal antibodies market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the North American cancer monoclonal antibodies market.
• Insights about market determinants which are stimulating the North American cancer monoclonal antibodies market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.